| COMPANY |
Liquidia Technologies is developing highly precise particle-based vaccines and therapeutics for the prevention and treatment of human disease. Combining a deep understanding of particle-based drug development with breakthrough small molecule and biological therapeutics, Liquidia is engineering vaccines and therapies that have the potential to dramatically improve the quality of human life. The company was founded in 2004 and is located in Research Triangle Park, North Carolina.
Learn more > |
|
| PRODUCT PLATFORM |
Utilizing a novel platform known as PRINT® technology, Liquidia is designing highly specific carriers for delivery of small molecules and biological cargos. This breakthrough platform technology makes it possible for the first time to design vaccines and therapies with precise control of particle size, shape, and composition.
Learn more >
|
|
| RECENT NEWS |
January 19, 2010
Liquidia raises $20 million Series C financing  Details
December 16, 2009
Liquidia receives $3MM NIST-TIP Award Details
September 24, 2009
Liquidia Founder Receives NIH Pioneer Award Details
June 22, 2009
Liquidia presents at AAPS National Biotechnology Conference. Details
June 11, 2009
Liquidia appoints Dr. Thomas Templeman as SVP Details
|
| |
|
